Triple-Drug attack shows promise for tough blood cancers
NCT ID NCT02846623
First seen Feb 17, 2026 · Last updated Jun 13, 2026 · Updated 14 times
Summary
This study tests a combination of three drugs (atezolizumab, obinutuzumab, and venetoclax) in about 50 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or Richter syndrome that has come back or not responded to prior treatment. The goal is to see if the combination can make the cancer undetectable at a very sensitive level (minimal residual disease negative). Participants receive the drugs intravenously and by mouth over several cycles, and researchers monitor side effects and response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.